P-014

P-014 is an investigational drug candidate being developed by Pangea Pharmaceuticals for the treatment of conditions associated with oxidative stress. Pangea Pharmaceuticals is a specialty pharmaceutical company that primarily focuses on the development of reformulated or generic versions of existing therapeutic agents, often utilizing the 505(b)(2) regulatory pathway or developing high-quality generics. P-014 is part of the company's internal pipeline (P-series codes), and while its specific active ingredient and molecular mechanism have not been publicly disclosed, it is intended to address pathological states where oxidative damage plays a significant role. Given Pangea's portfolio, P-014 is likely a small molecule therapeutic or a mineral-based formulation.